Kiromic BioPharma, Inc. (KRBP)
- Previous Close
2.7100 - Open
2.7500 - Bid --
- Ask --
- Day's Range
2.3775 - 3.0800 - 52 Week Range
0.1600 - 8.9700 - Volume
1,450 - Avg. Volume
6,785 - Market Cap (intraday)
3.968M - Beta (5Y Monthly) 2.01
- PE Ratio (TTM)
-- - EPS (TTM)
-12.5900 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
kiromic.comRecent News: KRBP
Performance Overview: KRBP
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRBP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRBP
Valuation Measures
Market Cap
3.97M
Enterprise Value
16.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.97
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-103.26%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.5M
Diluted EPS (ttm)
-12.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.2M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-14.23M